SCHEMBL4666959

SCHEMBL4666959

Cc1cc(C=Cc2cc3c(cc2Cn2cccn2)C(C)(C)CCC3(C)C)ccc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 7/20 0.48
RARB P10826 7/20 0.48
RARG P13631 7/20 0.48
RXRA P19793 16/20 0.41
RXRB P28702 5/20 0.41
RXRG P48443 5/20 0.41
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.35
CYP26A1 O43174 1/20 0.35
ABCB11 O95342 1/20 0.35
ESR1 P03372 1/20 0.35
PGR P06401 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
SLC6A2 P23975 1/20 0.35
ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666953 1.00 RARA (0.48) RARARARBRARGRXRARXRB
SCHEMBL4711958 0.90 RXRA (0.46) RARARARBRARGRXRARXRB
SCHEMBL14017862 0.90 RXRA (0.46) RARARARBRARGRXRARXRB
SCHEMBL4709671 0.90 RARA (0.38) RARARARBRARGRXRARXRB
SCHEMBL4709665 0.90 RARA (0.38) RARARARBRARGRXRARXRB
Palovarotene SCHEMBL4658931 0.89 RARB (0.57) RARARARBRARGRXRARXRB
Palovarotene SCHEMBL29354070 0.89 RARB (0.57) RARARARBRARGRXRARXRB
Palovarotene SCHEMBL4668028 0.89 RARB (0.57) RARARARBRARGRXRARXRB
SCHEMBL14159842 0.85 RARB (0.47) RARARARBRARGRXRARXRB
SCHEMBL14159856 0.84 RARA (0.46) RARARARBRARGRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1324970-B1 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA HOFFMANN LA ROCHE (CH) 2008-11-05 EP disclosed
EP-1935869-A1 Retinoids for the treatment of emphysema F. HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
US-6777418-B2 FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-08-17 US disclosed
EP-1324970-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2003-07-09 EP disclosed
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders SYNTEX (U.S.A.) LLC 2002-06-27 US disclosed
WO-2002028810-A2 RETINOIDS FOR THE TREATMENT OF EMPHYSEMA F. HOFFMANN-LA ROCHE AG (CH) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082265-A1 For treating or preventing emphysema, cancer and dermatological disorders RXRA, RXRG, RXRB RARA 5/4885RARB 6/4885RARG 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.